MA37455A1 - Utilisation d'un dérivé de pyrazole dans le traitement d'exacerbations aigues d'une maladie pulmonaire obstructive chronique - Google Patents
Utilisation d'un dérivé de pyrazole dans le traitement d'exacerbations aigues d'une maladie pulmonaire obstructive chroniqueInfo
- Publication number
- MA37455A1 MA37455A1 MA37455A MA37455A MA37455A1 MA 37455 A1 MA37455 A1 MA 37455A1 MA 37455 A MA37455 A MA 37455A MA 37455 A MA37455 A MA 37455A MA 37455 A1 MA37455 A1 MA 37455A1
- Authority
- MA
- Morocco
- Prior art keywords
- treatment
- pulmonary disease
- chronic obstructive
- obstructive pulmonary
- acute exacerbations
- Prior art date
Links
- 230000009798 acute exacerbation Effects 0.000 title abstract 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 title 1
- 150000003217 pyrazoles Chemical class 0.000 title 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
L'invention concerne l'utilisation de 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-méthylbenzamide ou d'un dérivé pharmaceutiquement acceptable de celui-ci dans la fabrication d'un médicament pour le traitement d'exacerbations aiguës d'une maladie pulmonaire obstructive chronique. Le traitement peut comprendre une dose unique du principe actif par administration par voie orale.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261613187P | 2012-03-20 | 2012-03-20 | |
| PCT/EP2013/055730 WO2013139809A1 (fr) | 2012-03-20 | 2013-03-19 | Utilisation d'un dérivé de pyrazole dans le traitement d'exacerbations aigues d'une maladie pulmonaire obstructive chronique |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA37455A1 true MA37455A1 (fr) | 2016-08-31 |
| MA37455B1 MA37455B1 (fr) | 2017-03-31 |
Family
ID=47901996
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA37455A MA37455B1 (fr) | 2012-03-20 | 2013-03-19 | Utilisation d'un dérivé de pyrazole dans le traitement d'exacerbations aigues d'une maladie pulmonaire obstructive chronique |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US9339491B2 (fr) |
| EP (1) | EP2827860B1 (fr) |
| JP (1) | JP6091593B2 (fr) |
| KR (1) | KR101793777B1 (fr) |
| CN (1) | CN104203234B (fr) |
| AU (1) | AU2013237503B2 (fr) |
| BR (1) | BR112014023107B1 (fr) |
| CA (1) | CA2866108C (fr) |
| CL (1) | CL2014002471A1 (fr) |
| CY (1) | CY1118327T1 (fr) |
| DK (1) | DK2827860T3 (fr) |
| ES (1) | ES2605942T3 (fr) |
| HR (1) | HRP20161514T1 (fr) |
| HU (1) | HUE032004T2 (fr) |
| IL (1) | IL234537A (fr) |
| LT (1) | LT2827860T (fr) |
| MA (1) | MA37455B1 (fr) |
| MX (1) | MX351996B (fr) |
| NZ (1) | NZ628392A (fr) |
| PH (1) | PH12014502107B1 (fr) |
| PL (1) | PL2827860T3 (fr) |
| PT (1) | PT2827860T (fr) |
| RU (1) | RU2625762C2 (fr) |
| SG (1) | SG11201404941WA (fr) |
| SI (1) | SI2827860T1 (fr) |
| TN (1) | TN2014000350A1 (fr) |
| TW (1) | TWI583381B (fr) |
| WO (1) | WO2013139809A1 (fr) |
| ZA (1) | ZA201405871B (fr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2600833C1 (ru) * | 2015-09-03 | 2016-10-27 | ФЕДЕРАЛЬНОЕ ГОСУДАРСТВЕННОЕ БЮДЖЕТНОЕ УЧРЕЖДЕНИЕ "РОССИЙСКИЙ НАУЧНЫЙ ЦЕНТР РАДИОЛОГИИ И ХИРУРГИЧЕСКИХ ТЕХНОЛОГИЙ" МИНИСТЕРСТВА ЗДРАВООХРАНЕНИЯ РОССИЙСКОЙ ФЕДЕРАЦИИ (ФГБУ "РНЦРХТ" Минздрава России) | Способ лечения хронической обструктивной болезни легких |
| RU2600822C1 (ru) * | 2015-09-03 | 2016-10-27 | ФЕДЕРАЛЬНОЕ ГОСУДАРСТВЕННОЕ БЮДЖЕТНОЕ УЧРЕЖДЕНИЕ "РОССИЙСКИЙ НАУЧНЫЙ ЦЕНТР РАДИОЛОГИИ И ХИРУРГИЧЕСКИХ ТЕХНОЛОГИЙ" МИНИСТЕРСТВА ЗДРАВООХРАНЕНИЯ РОССИЙСКОЙ ФЕДЕРАЦИИ (ФГБУ "РНЦРХТ" Минздрава России) | Способ лечения хронического обструктивного бронхита |
| KR102762199B1 (ko) * | 2016-03-08 | 2025-02-07 | 메레오 바이오파마 1 리미티드 | 만성 폐쇄성 폐 질환의 급성 악화 치료를 위한 투약법 |
| BR112018067784A2 (pt) * | 2016-03-08 | 2019-01-15 | Mereo Biopharma 1 Ltd | regime de dosagem para o tratamento de exacerbações agudas de condições inflamatórias |
| US10331542B2 (en) * | 2016-06-23 | 2019-06-25 | International Business Machines Corporation | System and method for detecting and alerting unexpected behavior of software applications |
| GB201612238D0 (en) * | 2016-07-14 | 2016-08-31 | Mereo Biopharma 1 Ltd | Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-Yl]-n-cyclopropyl-4-methylbenzamide |
| GB201612240D0 (en) | 2016-07-14 | 2016-08-31 | Mereo Biopharma 1 Ltd | Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide |
| BR112020006677A2 (pt) | 2017-10-05 | 2020-10-06 | Fulcrum Therapeutics, Inc. | uso de inibidores p38 para reduzir a expressão de dux4 |
| US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
| JP7280627B2 (ja) * | 2017-12-11 | 2023-05-24 | メレオ バイオファーマ １ リミテッド | 慢性閉塞性肺疾患の急性増悪の処置における３－［５－アミノ－４－（３－シアノベンゾイル）－ピラゾール－１－イル］－ｎ－シクロプロピル－４－メチルベンズアミドの使用 |
| AU2018381874B2 (en) | 2017-12-11 | 2024-08-15 | Mereo Biopharma 1 Limited | Use of 3-(5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl)-N-cyclopropyl-4-methylbenzamide in the prevention or reduction of acute exacerbations of chronic obstructive pulmonary disease |
| CN114141383A (zh) * | 2021-12-17 | 2022-03-04 | 湖南大学 | 慢阻肺智能护理方法、装置及系统 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2298743T3 (pl) | 2003-06-26 | 2013-02-28 | Novartis Ag | Inhibitory kinaz P38 na bazie 5-członowych heterocykli |
| GB0603684D0 (en) * | 2006-02-23 | 2006-04-05 | Novartis Ag | Organic compounds |
-
2013
- 2013-03-19 WO PCT/EP2013/055730 patent/WO2013139809A1/fr not_active Ceased
- 2013-03-19 HU HUE13710851A patent/HUE032004T2/en unknown
- 2013-03-19 DK DK13710851.0T patent/DK2827860T3/en active
- 2013-03-19 MA MA37455A patent/MA37455B1/fr unknown
- 2013-03-19 SI SI201330397A patent/SI2827860T1/sl unknown
- 2013-03-19 AU AU2013237503A patent/AU2013237503B2/en active Active
- 2013-03-19 PL PL13710851T patent/PL2827860T3/pl unknown
- 2013-03-19 BR BR112014023107-9A patent/BR112014023107B1/pt active IP Right Grant
- 2013-03-19 JP JP2015500892A patent/JP6091593B2/ja active Active
- 2013-03-19 ES ES13710851.0T patent/ES2605942T3/es active Active
- 2013-03-19 KR KR1020147025904A patent/KR101793777B1/ko active Active
- 2013-03-19 EP EP13710851.0A patent/EP2827860B1/fr active Active
- 2013-03-19 MX MX2014011291A patent/MX351996B/es active IP Right Grant
- 2013-03-19 NZ NZ628392A patent/NZ628392A/en unknown
- 2013-03-19 CA CA2866108A patent/CA2866108C/fr active Active
- 2013-03-19 CN CN201380015703.5A patent/CN104203234B/zh active Active
- 2013-03-19 SG SG11201404941WA patent/SG11201404941WA/en unknown
- 2013-03-19 LT LTEP13710851.0T patent/LT2827860T/lt unknown
- 2013-03-19 US US14/386,174 patent/US9339491B2/en active Active
- 2013-03-19 PT PT137108510T patent/PT2827860T/pt unknown
- 2013-03-19 TW TW102109739A patent/TWI583381B/zh active
- 2013-03-19 RU RU2014141893A patent/RU2625762C2/ru active
- 2013-03-19 HR HRP20161514TT patent/HRP20161514T1/hr unknown
-
2014
- 2014-08-11 ZA ZA2014/05871A patent/ZA201405871B/en unknown
- 2014-08-11 TN TNP2014000350A patent/TN2014000350A1/fr unknown
- 2014-09-08 IL IL234537A patent/IL234537A/en active IP Right Grant
- 2014-09-17 CL CL2014002471A patent/CL2014002471A1/es unknown
- 2014-09-22 PH PH12014502107A patent/PH12014502107B1/en unknown
-
2016
- 2016-04-29 US US15/143,356 patent/US20160243081A1/en not_active Abandoned
- 2016-11-18 CY CY20161101194T patent/CY1118327T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA37455A1 (fr) | Utilisation d'un dérivé de pyrazole dans le traitement d'exacerbations aigues d'une maladie pulmonaire obstructive chronique | |
| JOP20200222A1 (ar) | أشكال كريستالين لمثبط أنزيم كيناز تيروسين بروتون | |
| EP2571526A4 (fr) | Dispositifs d'administration de médicament pour administration d'agents thérapeutiques oculaires | |
| MD4539B1 (ro) | 4-Fenilpiridine substituite pentru tratamentul bolilor asociate cu receptorul NK-1 | |
| PH12015502628B1 (en) | Pyrazolopyrrolidine derivatives and their use in the treatment of disease | |
| JP2015057451A5 (fr) | ||
| EP2790668A4 (fr) | Minicellules intactes, d'origine bactérienne, pour l'administration d'agents thérapeutiques à des tumeurs cérébrales | |
| EA201491285A1 (ru) | Улучшенные композиции и способы доставки омепразола и ацетилсалициловой кислоты | |
| EP2683382A4 (fr) | Régimes posologiques pour le traitement de la maladie de fabry | |
| EP2869784A4 (fr) | Appareil oral pour l'administration d'un médicament | |
| EA201391689A1 (ru) | Система доставки лекарственного средства | |
| WO2015116856A3 (fr) | Antagonistes du récepteur x de farnésoïde | |
| EP2819741A4 (fr) | Implants de médicaments solides pour l'administration intracochléaire d'agents thérapeutiques pour le traitement de troubles otiques | |
| EP2981258A4 (fr) | Formulations pharmaceutiques pour l'administration sous-cutanée de furosémide | |
| EA201692298A1 (ru) | Производные карбоксамидов | |
| EP2676665A4 (fr) | Utilisation de la mangostine- dans la préparation de médicaments destinés à traiter la maladie d'alzheimer | |
| UA117154C2 (uk) | Антагоністи s1p3 | |
| EP3302443A4 (fr) | Microcapsules mécano-sensibles pour l'administration de médicaments | |
| JP2016538295A5 (fr) | ||
| FR2978046B1 (fr) | Formes posologiques pharmaceutiques de baclofene intrathecal et systeme d'administration associe | |
| EA201991359A1 (ru) | Фармацевтические лекарственные формы | |
| FI3903774T3 (fi) | N,N-bis-2-merkaptoetyyli-isoftalamidi neurodegeneratiivisten sairauksien hoitoon | |
| JP2017515849A5 (fr) | ||
| MX2017008497A (es) | Nuevos compuestos heterocíclicos y su uso tanto en medicina como en cosmética. | |
| MX372644B (es) | Una combinacion de unidades de dosificacion para su uso en el tratamiento del parto prematuro. |